SCHEMBL13137286

SCHEMBL13137286

CC(=O)c1[nH]c(=S)[nH]c1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
NPSR1 Q6W5P4 3/20 0.38
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 4/20 0.36
MAPK1 P28482 1/20 0.36
BRD4 O60885 2/20 0.34
BRPF1 P55201 2/20 0.34
CREBBP Q92793 2/20 0.34
RXFP1 Q9HBX9 1/20 0.33
HSD17B10 Q99714 1/20 0.32
LPO P22079 1/20 0.32
PTGS1 P23219 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MAPT P10636 2/20 0.32
HPGD P15428 1/20 0.31
EP300 Q09472 1/20 0.31
NSD2 O96028 1/20 0.31
CASP6 P55212 1/20 0.31
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10807093 0.76 KDM4E (0.38) CYP1A2NPSR1KDM4EALDH1A1MAPK1
SCHEMBL10877244 0.73 L3MBTL1 (0.50) CYP1A2CYP3A4NPSR1KDM4EALDH1A1
SCHEMBL276284 0.73 CYP1A2 (0.56) CYP1A2NPSR1KDM4EALDH1A1MAPK1
SCHEMBL9787264 0.69 LMNA (0.47) CYP1A2CYP3A4NPSR1ALDH1A1MAPK1
SCHEMBL9787252 0.68 PDE4A (0.45) CYP1A2CYP3A4NPSR1KDM4EALDH1A1
SCHEMBL28057359 0.66 CYP1A2 (0.61) CYP1A2CYP3A4NPSR1ALDH1A1MAPK1
SCHEMBL10138096 0.65 CYP1A2 (0.67) CYP1A2CYP3A4NPSR1ALDH1A1MAPK1
SCHEMBL7553005 0.62 L3MBTL1 (0.43) KDM4EALDH1A1BRPF1RXFP1HSD17B10
SCHEMBL24709647 0.62 CYP1A2 (0.50) CYP1A2CYP3A4NPSR1ALDH1A1MAPK1
SCHEMBL14123121 0.62 CYP1A2 (0.68) CYP1A2CYP3A4NPSR1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222328-A1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-02 US disclosed
US-20100204285-A1 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-08-12 US disclosed
US-20100016401-A1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Phamaceuticals Ltd. (CH) 2010-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204285-A1 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES HCRTR1, HCRTR2, CNR1 CYP1A2 642/4885CYP3A4 500/4885NPSR1 11/4885
US-20100016401-A1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES HCRTR1, HCRTR2, CNR1 CYP1A2 558/4885CYP3A4 683/4885NPSR1 14/4885
US-20100222328-A1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES HCRTR2, HCRTR1, NPY2R CYP1A2 423/4885CYP3A4 680/4885NPSR1 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.